Achaogen, Inc. (AKAO) Shares Bought by University of Notre Dame DU Lac

University of Notre Dame DU Lac raised its stake in shares of Achaogen, Inc. (NASDAQ:AKAO) by 49.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 155,654 shares of the biopharmaceutical company’s stock after purchasing an additional 51,786 shares during the quarter. University of Notre Dame DU Lac owned 0.37% of Achaogen worth $2,483,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in the company. Sigma Planning Corp lifted its holdings in shares of Achaogen by 9.6% in the 2nd quarter. Sigma Planning Corp now owns 9,450 shares of the biopharmaceutical company’s stock worth $205,000 after acquiring an additional 825 shares during the last quarter. Bank of Montreal Can lifted its holdings in shares of Achaogen by 33.3% in the 2nd quarter. Bank of Montreal Can now owns 10,000 shares of the biopharmaceutical company’s stock worth $217,000 after acquiring an additional 2,500 shares during the last quarter. Alps Advisors Inc. lifted its holdings in shares of Achaogen by 12.8% in the 3rd quarter. Alps Advisors Inc. now owns 41,593 shares of the biopharmaceutical company’s stock worth $663,000 after acquiring an additional 4,725 shares during the last quarter. Legal & General Group Plc bought a new stake in shares of Achaogen in the 2nd quarter worth approximately $168,000. Finally, Wells Fargo & Company MN lifted its holdings in shares of Achaogen by 34.3% in the 3rd quarter. Wells Fargo & Company MN now owns 33,213 shares of the biopharmaceutical company’s stock worth $530,000 after acquiring an additional 8,483 shares during the last quarter. Hedge funds and other institutional investors own 85.81% of the company’s stock.

Achaogen, Inc. (AKAO) opened at $10.50 on Wednesday. The company has a current ratio of 6.99, a quick ratio of 6.99 and a debt-to-equity ratio of 0.08. Achaogen, Inc. has a one year low of $4.82 and a one year high of $27.79.

Achaogen (NASDAQ:AKAO) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.13). Achaogen had a negative return on equity of 80.44% and a negative net margin of 593.61%. The firm had revenue of $0.58 million during the quarter, compared to analysts’ expectations of $2.09 million. During the same period in the previous year, the firm earned ($0.41) earnings per share. The firm’s quarterly revenue was down 96.4% compared to the same quarter last year. research analysts forecast that Achaogen, Inc. will post -3.06 EPS for the current year.

AKAO has been the subject of a number of recent research reports. Mizuho restated a “buy” rating and issued a $28.00 price objective on shares of Achaogen in a report on Thursday, November 30th. Stifel Nicolaus decreased their target price on shares of Achaogen from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, November 9th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Achaogen in a research note on Thursday, November 9th. Guggenheim began coverage on shares of Achaogen in a research note on Tuesday, October 24th. They issued a “buy” rating and a $17.00 target price on the stock. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $22.00 target price (down from $28.00) on shares of Achaogen in a research note on Monday, October 9th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $25.78.

In related news, COO Blake Wise sold 3,576 shares of Achaogen stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $15.99, for a total value of $57,180.24. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 8.36% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Achaogen, Inc. (AKAO) Shares Bought by University of Notre Dame DU Lac” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://stocknewstimes.com/2017/12/06/achaogen-inc-akao-shares-bought-by-university-of-notre-dame-du-lac.html.

Achaogen Company Profile

Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).

Want to see what other hedge funds are holding AKAO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achaogen, Inc. (NASDAQ:AKAO).

Institutional Ownership by Quarter for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply